Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin-Reference-Cited by-同舟云学术

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

Published:2018-01 Issue:1 Volume:93 Page:231-244
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Cherney David Z.I.,Cooper Mark E.,Tikkanen Ilkka,Pfarr Egon,Johansen Odd Erik,Woerle Hans J.,Broedl Uli C.,Lund Søren S.

Publisher

Elsevier BV

Subject

Nephrology

Reference39 articles.

1. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials;Musso;Ann Med,2012

2. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members;Chen;Diabetes Ther,2010

3. Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes;Heise;Clin Ther,2016

4. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial;Perkins;Diabetes Care,2014

5. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial;Haring;Diabetes Care,2013

Cited by 189 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. One-year Efficacy and Safety of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Study of Asian Patients;Clinical Therapeutics;2024-09

2. Financial Benefits of Renal Dose-Adjusted Dipeptidyl Peptidase-4 Inhibitors for Patients with Type 2 Diabetes and Chronic Kidney Disease;Endocrinology and Metabolism;2024-08-31

3. Management of chronic kidney disease: a Hong Kong consensus recommendation;Hong Kong Medical Journal;2024-08-27

4. Real‐world impact of adding a glucagon‐like peptide‐1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium‐glucose co‐transporter‐2 inhibitor: The Impact GLP‐1 CKD study;Diabetes, Obesity and Metabolism;2024-08-07

5. SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting Cardiovascular, Kidney, and Metabolic Health;Kidney Medicine;2024-08